Media Releases and Opportunities
Subscribe - HealthHealth
» Full news listing
Below you will find our most recent media releases and opportunities.Â
ºÚÁϳԹÏÍø congratulates its professors who have been recognized by the Royal Society of Canada (RSC) for their outstanding scholarly, scientific and artistic achievement.
This developing technology has many potential uses, including the ability to stimulate the diaphragm in people with ALS who are suffering from respiratory problems due to the loss of the motor neurons and synaptic connections that innervate their breathing muscles.
Dr. Christine Chambers and her team at the Halifax-based Centre for Pediatric Pain Research, have partnered with YummyMummyClub.ca (YMC) on a year-long social media campaign called It Doesn’t Have to Hurt. The work is funded by a grant from the Canadian Institutes of Health Research.
A researcher at ºÚÁϳԹÏÍøMedical School has developed a new way to deliver chemotherapy drugs. Using nanotechnology, the novel system releases chemo in cancerous cells only, leaving healthy cells alone. The work was recently published in Nature’s Scientific Reports.
Non-alcoholic fatty liver disease is now the most common form of liver disease in Canada and part of a larger liver-disease epidemic.
A major study that will provide in-depth understanding of aging has received a shot in the arm. The Canadian Longitudinal Study on Aging (CLSA) has been awarded a $41.6 million grant from the Canadian Institutes of Health Research (CIHR) to continue its work for the next five years.
–
Tuesday, January 20, 2015
In today's Canadian Foundation for Innovation announcement, eight of Dalhousie’s researchers have been awarded new infrastructure-related funding for their research into health and the environment..
ºÚÁϳԹÏÍøMedical School researchers are leading an international team of physicians and scientists that is investigating the role inflammation plays in rheumatoid arthritis and heart failure.
ºÚÁϳԹÏÍø is pleased to announce the appointment of Dr. David Anderson as dean of the Faculty of Medicine for a five-year term, effective July 1, 2015.
Scientists at ºÚÁϳԹÏÍøMedical School have successfully tested a never-before-used combination of drugs that effectively shuts down aggressive, metabolically active HER2-positive breast cancers.